Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 11.26B |
| Revenue (ttm) | 2.82B |
| Net Income (ttm) | 409.03M |
| Shares Out | 66.89M |
| EPS (ttm) | 6.07 |
| PE Ratio | 27.74 |
| Forward PE | n/a |
| Dividend | 2.50 (1.44%) |
| Ex-Dividend Date | Sep 12, 2025 |
| Volume | 72,180 |
| Average Volume | 49,891 |
| Open | 172.00 |
| Previous Close | 173.34 |
| Day's Range | 162.00 - 172.90 |
| 52-Week Range | 155.00 - 301.65 |
| Beta | -0.48 |
| RSI | 39.06 |
| Earnings Date | May 22, 2026 |
About Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2025, Jagsonpal Pharmaceuticals's revenue was 2.69 billion, an increase of 28.76% compared to the previous year's 2.09 billion. Earnings were 553.61 million, an increase of 146.45%.
Financial StatementsNews
Jagsonpal Pharmaceuticals Ltd (BOM:507789) Q3 2026 Earnings Call Highlights: Strategic Growth ...
Jagsonpal Pharmaceuticals Ltd (BOM:507789) Q3 2026 Earnings Call Highlights: Strategic Growth Amidst Market Challenges
Q3 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Q3 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Jagsonpal Pharmaceuticals shares decline nearly 3% today as revenue and EBITDA soften in Q2
Shares of Jagsonpal Pharmaceuticals traded lower on Tuesday, November 4, falling 2.86% to Rs 220 in morning trade, after the...
Jagsonpal Pharmaceuticals shares drop 2.6% after USFDA issues warning letter for manufacturing lapses at API plant
Jagsonpal Pharmaceuticals shares fell over 2% after the US Food and Drug Administration (USFDA) issued a warning letter citing significant manufacturing lapses at its Rajasthan-based active pharmaceut...
Jagsonpal Pharmaceuticals acquires Resilient Cosmeceuticals’ India business for Rs 24 crore
Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) has announced the acquisition of Resilient Cosmeceuticals Private Limited’s India business for ₹24 crore. The deal, funded through inte...
Jagsonpal Pharmaceuticals shares jump nearly 6% on strong Q3 FY25 results
Jagsonpal Pharmaceuticals Limited shares surged nearly 6% on January 23, 2025, following the announcement of its robust Q3 FY25 financial performance. The stock traded at ₹241, up by ₹12.75, reflectin...
Jagsonpal Pharmaceuticals block trade: 22 lakh shares exchanged in ₹88 crore deal
On September 6, 2024, JAGSNPHARM witnessed a significant block trade during Session 1, with 22,00,000 shares exchanging hands at a steady price of ₹400.00. Despite the large transaction, the stock clo...